by dschulz September 15, 2023 in Lectenz® Bio News 0 0 The National Institutes of Health (NIH) National Institute of General Medical Sciences (NIGMS) awards Lectenz Bio an SBIR Phase II to further develop the GlycoSense™ technology for monitoring glycosylation during glycoprotein production. Related Posts Lectenz Bio receives NIH SBIR Phase IIThe National Institute of General Medical Sciences (NIGMS) awards Lectenz Bio an SBIR Phase II to further develop… Lectenz Bio receives NIH SBIR Phase IThe National Institute of General Medical Sciences (NIGMS) awards Lectenz Bio a second SBIR Phase I to apply… Lectenz Bio receives NIH NIGMS SBIR Phase IThe NIH National Institute of General Medical Sciences (NIGMS) awards Lectenz Bio an SBIR Phase I to develop fucose binding… Related Posts CEO Lori Yang Co-Authored Nature Communications Paper, Featuring SiaFind™ GlycoSense Paper Published in Scientific Reports
